indole, indolylmaleimides, antitumor drugs, protein kinases, protein kinase inhibitors.
Abstract
Several previously unknown derivatives of 3,4-bis(indol-1-yl)maleimide, as well as 3-(2,3-dihydroindol-1-yl)-4-(indol-1-yl)maleimide were synthesized as potential analogs for a known series of protein kinase inhibitors BIS I, IV, IX containing the structural motif of 3,4-bis(indol-3-yl)maleimide. The activity of these synthesized compounds was characterized with regard to several human protein kinases and their cytotoxicity was determined.
Author Biographies
Алексей А. Панов, Gause Institute of New Antibiotics,
11 Build. 1 B. Pirogovskaya St., Moscow 119021, Russia;
м.н.с Лаборатории Химической Трансформации Антибиотиков
Михаэль Х. Г. Куббутат, ProQinase GmbH, Tumor Biology Centre in Freiburg,
117 Breisacher St., Freiburg 79106, Germany
Head of Biochemical Drug Discovery & Head of Drug Development
Любовь Г. Деженкова, N. N. Blokhin Russian Cancer Research Center,
24 Build. 2 Kashirskoye Shosse, Moscow 115478, Russia
с.н.с. Лаборатории Химической Трансформации Антибиотиков
Кристоф Шехтеле, ProQinase GmbH, Tumor Biology Centre in Freiburg,
117 Breisacher St., Freiburg 79106, Germany
